Market Cap: $901.56M
VI
Verastem, Inc.
VSTM
NASDAQ (NASDAQ Global Market)USD
Market Cap: $901.56M
Verastem (Ticker: VSTM), a biotechnology company dedicated to advancing cancer therapies, celebrates a significant advancement in its clinical pipeline following successful trial results for its pancr…
Verastem Inc. Reports Strong Q4 Earnings Amid Promising Oncology Pipeline Verastem Inc. (NASDAQ: VSTM) reveals a robust financial performance in its Q4 earnings report, marking a notable milestone in…
### Verastem's Commitment to Oncology Progress Amidst Financial Growth Verastem Inc. (NASDAQ: VSTM) showcases a significant milestone in its quarterly earnings report released on March 4, 2026, emphas…
Verastem’s Emerging Strength in Cancer Treatment: A Positive Q4 Earnings Review Verastem Inc. (NASDAQ: VSTM) recently announces its Q4 earnings for 2026, revealing notable advancements in its financia…
### Verastem Oncology Discontinues RAMP 203 Trial, Reevaluates Research Focus Verastem Oncology announces the discontinuation of its RAMP 203 trial, which was aimed at assessing the effectiveness of a…
Verastem Oncology Discontinues RAMP 203 Trial Amid Efficacy Concerns Verastem Oncology announces its decision to halt the RAMP 203 trial, which targets advanced KRAS G12C–mutated non-small cell lung c…
Verastem Focuses on Advancing Drug Development Amid Market Volatility Verastem, a biotechnology company dedicated to advancing treatment options for cancer, remains steadfast in its mission to develop…
Verastem's Progress in Cancer Treatment: Advancing Targeted Therapies Verastem Oncology focuses on developing and commercializing innovative therapies for cancer treatment, emphasizing targeted therap…
Verastem's Position in the Evolving Oncology Market Verastem, a biotechnology company focused on developing and commercializing therapies for cancer, stands at a pivotal moment in the oncology sector.…
Verastem’s Strategic Focus on Cancer Treatment Innovations Verastem, a biotechnology company specializing in developing therapies for cancer treatment, is actively advancing its research initiatives t…
Verastem Oncology Advances Innovative Cancer Treatment in Phase 1/2 Trial Verastem Oncology Inc. is making significant strides in cancer treatment with the latest data from its Phase 1/2 clinical tria…
Verastem Oncology Advances Precision Medicine with Promising Trial Data for GFH375 Verastem Oncology Inc. announces encouraging results from the dose escalation phase of its Phase 1/2 clinical trial f…
Verastem's Accelerated Approval for Targeted Ovarian Cancer Therapy Verastem Inc. achieves a significant milestone with the FDA's recent accelerated approval of its VSTM Avmapki Fakzynja Co-pack, a co…
Verastem Secures FDA Approval for Innovative Cancer Therapy Targeting KRAS Mutations Verastem Inc. achieves a significant milestone with the recent accelerated approval from the Food and Drug Administ…
Verastem Oncology's Commitment to Advancing Cancer Treatments Verastem Oncology, a biopharmaceutical company dedicated to developing new therapies for RAS/MAPK pathway-driven cancers, is set to highli…
Verastem Oncology: Pioneering Treatments for RAS/MAPK Pathway-Driven Cancers Verastem Oncology, a biopharmaceutical company specializing in innovative treatments for RAS/MAPK pathway-driven cancers, i…
Verastem Oncology Appoints New COO Amid Strategic Transition Verastem Oncology, a biopharmaceutical company dedicated to developing treatments for cancers driven by the RAS/MAPK pathway, announces the…
Verastem Oncology Strengthens Leadership with New COO Appointment Verastem Oncology, a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, appoints Matthew…
Verastem Oncology Strengthens Workforce with Strategic Talent Acquisition Verastem Oncology, a biopharmaceutical company dedicated to developing innovative cancer therapies, actively enhances its work…
Verastem Oncology Enhances Talent Acquisition with Strategic Stock Option Grant Verastem Oncology, a biopharmaceutical company dedicated to advancing innovative cancer treatments, has recently announc…
Verastem Oncology Advances Cancer Treatment with FDA Acceptance of New Drug Application Verastem Oncology, a biopharmaceutical company dedicated to developing innovative cancer therapies, announces th…
Verastem Oncology's Promising Triplet Therapy for KRAS G12C Mutant NSCLC Shows Early Promise Verastem Oncology (Nasdaq: VSTM) is making significant strides in the development of a triplet combination…
Promising Developments in Verastem Oncology’s Triplet Therapy for NSCLC Verastem Oncology, a biopharmaceutical firm dedicated to innovating cancer treatments, announces notable preliminary clinical re…
Verastem Oncology to Showcase Innovations in Cancer Treatment at Upcoming Conference Verastem Oncology, a prominent biopharmaceutical company, is set to engage stakeholders in a fireside chat at the 7…
Verastem Oncology Prepares for Insightful Conference on Cancer Treatment Innovations Verastem Oncology, a prominent player in the biopharmaceutical sector, is set to participate in the 7th Annual Ever…